CD274 and non-small cell lung carcinoma: Several retrospective analyses showed that not smoking, PS 2, bone and liver metastases are independent predictive negative factors for OS in advanced NSCLC patients with PD-L1 ≥ 50% treated with first-line pembrolizumab [15, 16, 18].